Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats
CONCLUSION: MF maintains anti-inflammatory activity when administered by systemic routes and exerts less impact on metabolism when administered orally in male and female rats, effects that are GR-dependent and reversible. Category: Metabolic Disorders and Endocrinology.PMID:36893817 | DOI:10.1016/j.bcp.2023.115486 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Priscila L Zimath Milena S Almeida Maciel A Bruxel Alex Rafacho Source Type: research
Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats
CONCLUSION: MF maintains anti-inflammatory activity when administered by systemic routes and exerts less impact on metabolism when administered orally in male and female rats, effects that are GR-dependent and reversible. Category: Metabolic Disorders and Endocrinology.PMID:36893817 | DOI:10.1016/j.bcp.2023.115486 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Priscila L Zimath Milena S Almeida Maciel A Bruxel Alex Rafacho Source Type: research
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study
A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler ® is the first inhaled corticosteroid/long-acting ꞵ2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment of asthma in adults inadequately controlled on ICS/LABA combination. In patients with asthma and persistent airflow limitation (PAL), maxim al treatment, especially with combination is suggested. This post hoc analysis of data from the IRIDIUM study assessed the efficacy of MF/IND/GLY in asthma patients with and without ...
Source: Respiratory Medicine - March 8, 2023 Category: Respiratory Medicine Authors: Richard N. Van Zyl-Smit, Huib AM. Kerstjens, Jorge F. Maspero, Konstantinos Kostikas, Motoi Hosoe, Ana- Maria Tanase, Peter D'Andrea, Karen Mezzi, Dominic Brittain, David Lawrence, Kenneth R. Chapman Tags: Original Research Source Type: research
Effect of an Intranasal Corticosteroid in Young Children With Chronic Rhinosinusitis
This randomized clinical trial presents data about the clinical efficacy and changes in nasopharyngeal microbiome in children aged 4 to 8 years after treatment with intranasal mometasone furoate for chronic rhinosinusitis. (Source: JAMA Pediatrics)
Source: JAMA Pediatrics - February 27, 2023 Category: Pediatrics Source Type: research
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
(Source: Journal of Asthma and Allergy)
Source: Journal of Asthma and Allergy - January 19, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Methotrexate for recurrent chronic rhinosinusitis with nasal polyps: A randomized, controlled, phase 2 clinical trial
ConclusionLow-dose MTX was a safe and effective maintenance therapy for patients with recurrent postoperative CRSwNPs. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - January 19, 2023 Category: Allergy & Immunology Authors: Asli Cakir Cetin,
Yesim Tuncok,
Pembe Keskinoglu,
Mualla Aylin Arici,
Fatos Onen,
Mustafa Cenk Ecevit Tags: ORIGINAL ARTICLE Source Type: research
Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children
This randomized clinical trial investigates the effectiveness of intranasal mometasone furoate compared with intranasal saline for the treatment of obstructive sleep-disordered breathing in children. (Source: JAMA Pediatrics)
Source: JAMA Pediatrics - January 17, 2023 Category: Pediatrics Source Type: research
Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - January 14, 2023 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Methotrexate for recurrent chronic rhinosinusitis with nasal polyps: A randomized controlled phase II clinical trial
ConclusionLow-dose MTX was a safe and effective maintenance therapy for patients with recurrent postoperative CRSwNP.This article is protected by copyright. All rights reserved (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - December 28, 2022 Category: Allergy & Immunology Authors: Asli CAKIR CETIN,
Yesim TUNCOK,
Pembe KESKINOGLU,
Mualla Aylin ARICI,
Fatos ONEN,
Mustafa Cenk ECEVIT Tags: ORIGINAL ARTICLE Source Type: research
Efficacy of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of salmeterol/fluticasone (SAL/FLU) & tiotropium (TIO) in patients with uncontrolled asthma on prior LABA/ICS high-dose (GINA step 5): Results from ARGON study
Conclusion: In patients uncontrolled on LABA/ICS high-dose, efficacy of single inhaler IND/GLY/MF (high- and medium-dose) o.d. was similar to SAL/FLU high-dose b.i.d. & TIO o.d. via two different inhalers with two different dosing regimens, suggestive of potential clinical benefit of this treatment option over the current standard of care. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Gessner, C., Lawrence, D., Mezzi, K., Brittain, D., Van-Zyl Smit, R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Medication adherence and asthma control with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler(R) digital companion: interim analysis from Japan and Germany
Conclusions: Pts using Breezhaler® digital companion showed good medication adherence (>85% over 3 months) and improved asthma control. Further analysis/study is required to account for observed differences between countries. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Woehrle, H., Mastoridis, P., A Stempel, D., Kaye, L., Vuong, V., Mezzi, K. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Medication adherence and asthma control with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler(R) digital companion: interim analysis from Europe
Conclusions: Pts using Breezhaler® digital companion showed good medication adherence (≥92% over 6 months) which did not decline over time and improved asthma control. Long-term studies may be required to confirm these findings. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Woehrle, H., Mastoridis, P., A Stempel, D., Kaye, L., Vuong, V., Mezzi, K. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study
Conclusion: High-dose MF/IND/GLY provided similar benefits irrespective of baseline subgroups. Physicians looking to personalise treatment decision would be better served looking to pts preference factors (e.g., o.d./b.i.d. regimen, device type, availability of digital companion) than those clinical parameters explored here. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Kerstjens, H. A., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Chapman, K. R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis
Conclusion: The patient characteristics analysed (age, age of asthma onset & BMI) do not significantly impact positive outcomes when using single inhaler o.d. IND/GLY/MF vs free combination of twice daily (b.i.d.) SAL/FLU & o.d. TIO. Therefore, treatment personalisation in terms of patient preference (e.g., convenience of o.d. vs b.i.d. regimen, single inhaler, device type) would be more appropriate. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Van Zyl-Smit, R., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Gessner, C. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice-daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma
Conclusion: Both doses of MF/IND/GLY taken once daily (a.m.) improved lung function and controlled symptoms throughout the day and during the night, more effectively than twice daily high-dose FLU/SAL. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Chapman, K. R., Van-Zyl Smit, R., Mezzi, K., Brittain, D., Kerstjens, H. A. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
